NYSE:MNK - Mallinckrodt Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$31.07 -0.53 (-1.68 %)
(As of 11/13/2018 04:00 PM ET)
Previous Close$31.60
Today's Range$30.83 - $32.34
52-Week Range$11.65 - $36.65
Volume2.07 million shs
Average Volume3.15 million shs
Market Capitalization$2.57 billion
P/E Ratio4.15
Dividend YieldN/A
Beta1.71
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:MNK
Previous Symbol
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio0.93
Current Ratio2.21
Quick Ratio2.05

Price-To-Earnings

Trailing P/E Ratio4.15
Forward P/E Ratio4.38
P/E Growth0.41

Sales & Book Value

Annual Sales$3.22 billion
Price / Sales0.80
Cash Flow$16.3526 per share
Price / Cash1.90
Book Value$68.65 per share
Price / Book0.45

Profitability

EPS (Most Recent Fiscal Year)$7.49
Net Income$2.13 billion
Net Margins65.24%
Return on Equity9.60%
Return on Assets4.12%

Miscellaneous

Employees3,900
Outstanding Shares83,310,000
Market Cap$2.57 billion
OptionableOptionable

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt announced that its board has approved a stock repurchase program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 18.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings data on Tuesday, November, 6th. The company reported $2.10 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.79 by $0.31. The company had revenue of $640 million for the quarter, compared to analyst estimates of $634.38 million. Mallinckrodt had a net margin of 65.24% and a return on equity of 9.60%. The business's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.97 EPS. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Mallinckrodt.

What guidance has Mallinckrodt issued on next quarter's earnings?

Mallinckrodt updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $7.00-7.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.75. Mallinckrodt also updated its FY 2018 guidance to $7.00-7.20 EPS.

What price target have analysts set for MNK?

17 Wall Street analysts have issued twelve-month price targets for Mallinckrodt's shares. Their forecasts range from $20.00 to $58.00. On average, they expect Mallinckrodt's stock price to reach $32.6250 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View Analyst Price Targets for Mallinckrodt.

What is the consensus analysts' recommendation for Mallinckrodt?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 3 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:
  • 1. Mizuho analysts commented, "We reiterate our Neutral rating into what we view as risky read-outs for VTS-270 in Niemann- Pick Type C, and CPP-1X/Sulindac in FAP." (11/6/2018)
  • 2. According to Zacks Investment Research, "The year 2018 is expected to be a transformative year for Mallinckrodt as the company strives to revive its product portfolio/pipeline. The hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting sales. The company also upped its annul guidance. The Sucampo buyout will diversify the company’s portfolio considering Amitiza’s potential. The company is currently streamlining its business to focus better on its innovative medicines and therapies like terlipressin and StrataGraft. The recent restructuring efforts are encourgaing as the company has been in troubled waters for quite some time now. Shares have outperformed the industry in the year so far. However, sales of Acthar continue to decline due to the residual impact of patient withdrawal issues thereby adversely impacting the top-line as the drug is the lead product of the company. The CRL for  stannsoporfin was disappointing." (10/9/2018)
  • 3. Canaccord Genuity analysts commented, "We were pleasantly surprised by Mallinckrodt’s 2Q/18 beat and raise last week as the story continues to evolve toward higher pipeline science and away from Acthar- related drama. However, with strong momentum behind MNK shares of late, we remain concerned about external forces on Acthar or internal pipeline setbacks potentially squelching momentum in the story." (8/13/2018)

Has Mallinckrodt been receiving favorable news coverage?

Headlines about MNK stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mallinckrodt earned a news impact score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Mallinckrodt's key competitors?

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
  • Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 55)
  • Ms. Kathleen A. Schaefer, Sr. VP, Principal Accounting Officer & Corp. Controller

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.48%), Dimensional Fund Advisors LP (6.62%), LSV Asset Management (4.06%), Prudential Financial Inc. (2.34%), FMR LLC (2.22%) and Royce & Associates LP (1.28%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.

Which institutional investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Schneider Capital Management Corp, Connor Clark & Lunn Investment Management Ltd., FMR LLC, Robeco Institutional Asset Management B.V., Robeco Institutional Asset Management B.V., Royce & Associates LP and SG Americas Securities LLC. View Insider Buying and Selling for Mallinckrodt.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Prudential Financial Inc., Acadian Asset Management LLC, LSV Asset Management, Renaissance Technologies LLC, Allianz Asset Management GmbH, Capital Growth Management LP and Seven Eight Capital LP. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $31.07.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $2.57 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is http://www.mallinckrodt.com.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (NYSE MNK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  698 (Vote Outperform)
Underperform Votes:  466 (Vote Underperform)
Total Votes:  1,164
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel